Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life

Pediatric Infectious Disease Journal

Volumn 24, Issue 6, 2005, Pages 503-509

  Kovacs, Andrea ^a   Cowles, Mary Kathryn ^b   Britto, Paula ^c   Capparelli, Edmund ^d   Fowler, Mary Glenn ^e,j   Moye, Jack ^f   McIntosh, Ken ^g   Rathore, Mobeen H ^h   Pitt, Jane ⁱ   Husson, Robert N ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

ⁱ New York Presbyterian Columbia University Medical Center   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

Didanosine; Early Treatment; Human Immunodeficiency Virus; Infant; Mutations; Pharmacokinetics; Resistance; Zidovudine

Indexed keywords

DIDANOSINE; LAMIVUDINE; LEUCINE; METHIONINE; NEVIRAPINE; PHENYLALANINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; THREONINE; TYROSINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; DOSE CALCULATION; DRUG CLEARANCE; DRUG TOLERANCE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MUTATION; NEUTROPENIA; PANCREATITIS; PERINATAL DRUG EXPOSURE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 20544478213     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000164787.63237.0b     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection [published erratum appears in MMWR. 1998;47:315]. MMWR. 1998;47:1-43.
2. U.S. Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. November 26, 2003. Available at: http://AIDSinfo.nih.gov.
3. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR. 1994;43:1-20.
4. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States [published errata appear in MMWR. 1998;47:287 and MMWR. 1998;47:315]. MMWR. 1998;47:1-30.
5. DeRemer M, D'Ambrosio R, Morse GD. Didanosine measurement by radioimmunoassay. Antimicrob Agents Chemother. 1996;40:1331-1334.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004;12:119-124.
7. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
8. McSherry GD, Shapiro DE, Coombs RW, et al. The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr. 1999;134:717-724.
9. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis. 1998;177:557-564.
10. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women: Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis. 1999;179:705-708.
11. Masquelier B, Chaix ML, Burgard M, et al. Zidovudine genotypic resistance in HIV-1-infected newboms in the French perinatal cohort. J Acquir Immune Defic Syndr. 2001;27:99-104.
12. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newboms. J Acquir Immune Defic Syndr. 2003;32:292-297.
13. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS. 2004;18: 237-245.
14. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA. 1996;93:5501-5506.
15. Loveday C. International perspectives on antiretroviral resistance: nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26(suppl 1):S10-S24.
16. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis. 2001;184:1120-1126.
17. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis. 2001;183:1688-1693.
18. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study: the Women and Infants Transmission Study Group. AIDS. 2000;14:263-271.
19. Pemo CF, Cozzi-Lepri A, Forbici F, et al. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis. 2004;189:1983-1987.
20. Pemo CF, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis. 2001;184:983-991.
21. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol. 1999;59:364-368.
22. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol. 2000;74:6262-6268.
23. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis. 1998; 177: 1521-1532.
24. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359: 1178-1186.
25. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992;165:99-104.
26. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol. 2003;43:133-140.
27. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics. 1994;94:724-731.
28. Pereira CM, Nosbisch C, Unadkat JD. Pharmacokinetics of dideoxyinosine in neonatal pigtailed macaques. Antimicrob Agents Chemother. 1994;38:787-789.
29. Drusano GL, Yuen GJ, Morse G, et al. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob Agents Chemother. 1992;36:1280-1283.